Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | — | — | ~25 | ~R 549 414 PFS proxy · indirect | 1 |
Pazopanib monotherapy Variant #01 | — | R 22 754 | 28d | ~4.3 mo | — | ~26 | ~R 591 593 PFS proxy · indirect | 3 |
Pegylated liposomal doxorubicin monotherapy Variant #02 | — | R 8 000 | 28d | ~4.2 mo | ~13.5 mo | ~6 | ~R 48 000 PFS proxy · indirect | 24 |
Methotrexate and Vinblastine Variant #01 | — | R 3 108 | 14d | — | — | ~26 | ~R 60 610 indirect | — |
Imatinib monotherapy Variant #16 | — | R 1 401 | 28d | ~20.0 mo | ~53.0 mo | ~14 | ~R 19 610 PFS proxy · indirect | 8 |
Nirogacestat monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | 1 |
Placebo Partial | — | — | — | — | — | — | — | 2 |
7 of 7 regimens shown